Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 18, 2011Blood

Disruption of MYD88 Pathway Signaling Leads to Loss of Constitutive IRAK1, NF-κβ and JAK/STAT Signaling and Induces Apoptosis of Cells Expressing the MYD88 L265P Mutation in Waldenstrom's Macroglobulinemia

View Full Paper
Ask AI
Bookmark
Share

Population

Primary Waldenstrom's Macroglobulinemia lymphoplasmacytic cells from bone marrow biopsy specimens, BCWM.1…

Comparison

Inhibitors of MYD88 homodimerization and IRAK… vs Untreated cells and MYD88 wild type expressing…

Design

Preclinical

Authors

GYGuang YangYZYangsheng ZhouXLXia Liu

Discussion

Loading...

Member takes

Overview

Hypothesis-generating for MYD88/IRAK inhibition in L265P-mutated WM; human trials needed before clinical adoption.

Structured PICO

P
Population
Primary Waldenstrom's Macroglobulinemia (WM) lymphoplasmacytic cells (LPCs) from bone marrow biopsy specimens, BCWM.1 and MWCL-1 cell lines (MYD88 L265P mutated), Ramos and MM1S cell lines, and CD19+ B-cells from healthy donors
I
Intervention
Inhibitors of MYD88 homodimerization (IMG-2005-5) and IRAK 1/4 kinase function (407601)
C
Comparator
Untreated cells and MYD88 wild type expressing cells (Ramos, MM1S, healthy donor CD19+ B-cells)
O
Outcome
Phosphorylation of MYD88 downstream signaling proteins (IRAK1, IκBα, NFκβ-p65, STAT3) and apoptosissurrogate

Disruption of MYD88 pathway signaling induces apoptosis in Waldenstrom's Macroglobulinemia cells expressing the MYD88 L265P mutation, providing a framework for clinical investigation of these inhibitors.

Cite This Study

Yang et al. (2011) studied this question.

synapsesocial.com/papers/6a7df2a5d0946debe91507f4https://doi.org/10.1182/blood.v118.21.597.597
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MYD88 L265P mutation in Waldenstrom macroglobulinemia2013 · 232 citations
  2. 2MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia2012 · 1,300 citations
  3. 3<i>MYD88</i> gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies2026
  4. 4LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK2025
  5. 5Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 20252026